Skip to main content
. 2015 Nov 17;2015(4):47. doi: 10.5339/gcsp.2015.47

Figure 3.

Figure 3.

Impact of BMP9 therapy on pulmonary endothelial cell function. In the lungs of PAH patients, loss of BMPR-II leads to endothelial dysfunction, including increased vascular permeability, apoptosis and aberrant angioproliferation. Therapeutic delivery of recombinant BMP9 promotes endothelial quiescence, survival and vascular integrity, while simultaneously enhancing BMPR-II expression.